Triochem Products Limited has announced a separate Board Meeting of Independent Directors scheduled for March 20, 2026, in compliance with regulatory requirements. The meeting represents a key governance milestone for the Mumbai-based chemical products company.

Meeting Details and Regulatory Compliance

The independent directors' meeting has been scheduled under Regulation 25(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and provisions of Section 173 and Schedule IV of the Companies Act, 2013. The meeting will be held on Friday, March 20, 2026, at 3:00 PM at the company's registered office.

Key Agenda Items

The independent directors will deliberate on several critical governance matters during the meeting. The agenda encompasses comprehensive performance reviews and assessment of board effectiveness.

The meeting will address the following key areas:

• Review the performance of Non-Independent Directors and the Board of Directors as a whole
• Review the performance of the Chairperson of the Company
• Assess the quality, quantity and timeliness of flow of information between company management and the Board
• Consider any other business with the permission of the chair

Corporate Governance Framework

This separate meeting of independent directors forms part of the company's structured corporate governance framework. The evaluation process ensures independent oversight of board performance and management effectiveness. The assessment of information flow between management and the board is particularly significant for ensuring directors can perform their duties effectively.

Company Information

Triochem Products Limited operates from its registered office in Mumbai's Fort area. The company secretary and compliance officer Ureca Deolekar signed the intimation notice dated March 13, 2026. The company maintains its corporate website at www.triochemproducts.com and can be contacted via email at info@amphray.com .

Triochem Products Limited has re-submitted its unaudited standalone financial results for the quarter and nine months ended 31st December 2025 to BSE Limited, following regulatory observations regarding a typographical error in the Limited Review Report. The pharmaceutical company corrected the period mentioned in the report from December 31, 2024 to December 31, 2025.

Financial Performance Overview

The company's financial performance for Q3FY26 showed challenging results across key metrics:

For the nine-month period ended December 31, 2025, the company reported a net loss of Rs. 35.50 lakhs compared to a net profit of Rs. 5.17 lakhs in the corresponding period of the previous year.

Regulatory Compliance and Re-submission

BSE Limited had issued a non-compliance notice dated 20th February 2026 under Regulation 33 of SEBI (LODR) Regulations, 2015, highlighting the typographical error in the Limited Review Report. The company acknowledged the error and confirmed that there were no changes in the actual financial results, only the correction of the wrong period mentioned in the auditor's report.

The Board of Directors approved the financial results at its meeting held on Friday, 13th February 2026, with Mr. Ramu S. Deora, Director, serving as the Chairperson of the meeting.

Operational and Strategic Developments

The company operates in a single segment of chemicals and pharmaceuticals. During the period, Triochem Products received shareholder approval on 13th December 2025 for the sale of immovable properties, plant & machinery, and investment property situated in Maharashtra.

The assets have been classified as 'Assets Held for Sale' in accordance with Ind AS 105, with the transaction expected to be completed on or before 31st March 2026. The proceeds are intended for new business ventures and strategic initiatives.

Expense Analysis

The company's expense structure for Q3FY26 included employee benefit expenses of Rs. 14.44 lakhs, other expenditure of Rs. 23.62 lakhs, and depreciation expenses of Rs. 1.36 lakhs, totaling Rs. 39.42 lakhs against total income of Rs. 22.06 lakhs.

The financial results were reviewed by the Audit Committee and approved by the Board of Directors, with statutory auditors Kanu Doshi Associates LLP providing an unqualified review conclusion on the statements.